Overall we achieved the original time-to-event information from 4 trials on DPP-4 inhibitors (CARMELINA, EXAMINE, SAVOR-TIMI 53, TECOS), 7 trials on GLP-1 receptor agonists (ELIXA, EXSCEL, HARMONY, LEADER, PIONEER, REWIND, SUSTAIN), and 8 trials on SGLT2 inhibitors (CANVAS, CREDENCE, DAPA-CKD, DAPA-HF, DECLARE-TIMI 58, EMPA-REG, EMPEROR-REDUCED, VERTIS-CV). The gene discussed is DPP4; the disease is chronic kidney disease.